Week In Review: BeiGene Plans $2.5 Billion IPO On Shanghai Star Exchange

BeiGene is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. BeiGene announced China approval to market Xgeva (denosumab) to prevent skeletal-related events (SREs) in …
( read original story …)